Effect of Gallic acid and Myricetin on ovarian cancer models: a possible alternative antitumoral treatment.

Luis Varela-Rodríguez Blanca Sánchez-Ramírez Verónica Ivonne Hernández-Ramírez Hugo Varela-Rodríguez Rodrigo Daniel Castellanos-Mijangos Carmen González-Horta Bibiana Chávez-Munguía Patricia Talamás-Rohana

Published in: BMC complementary medicine and therapies (2020)

GA and Myr (50 mg/kg) administered by peritumoral route, inhibit ovarian tumor lesions development in rodents with some toxicological effects. Additional studies will be necessary to find the appropriate therapeutic dose for GA. Therefore, GA and Myr could be considered as a starting point for the development of novel anticancer agents.

Keyphrases

pet ct
case control
replacement therapy